Abstract:Abstract Background Oxidative stress leads to adverse atrial remodeling in diabetes mellitus. AMP-activated protein kinase (AMPK) agonists have been shown to prevent cardiomyocytes from oxidative stress by improving mitochondrial function, but their underlying mechanisms are not completely understood. This study investigated the molecular changes and their underlying regulatory mechanisms by the AMPK agonists, metformin and AICA ribonucleotide (AICAR). Methods Mouse atrial cardiomyocytes (HL-1 cells) and rats with type 2 diabetes mellitus (DM) were used as study models. A total of 40 rats were randomly divided into control, DM alone, DM treated with metformin, AICAR, or metformin with the AMPK inhibitor Compound C. Echocardiographic, hemodynamic, and electrophysiological measurements were made in vivo . Reactive oxygen species (ROS) production rate and mitochondrial membrane potential (MMP) levels were performed in vitro . Protein expression of SOD, COX43 and mitochondrial biogenesis related proteins were measured using Western blotting. Results Compared with controls, the diabetes group demonstrated larger left atrial diameter and fibrosis area associated with a higher incidence of inducible atrial fibrillation (AF). Lower Mn-SOD, COX42, and mitochondrial biogenesis (PGC-1α, NRF1 and TFAM)-related proteins were observed, accompanied by mitochondrial swelling. Metformin treatment led to reversal of structural remodeling and lower inducible AF incidence, which were associated with higher Mn-SOD, COX42, and biogenesis-related proteins as well as improvement in the structure and function of mitochondria. Similar protective changes were observed following AICAR or metformin with Compound C treatment. In HL-1 cell line, compared with controls, the DM group demonstrated higher mitochondrial ROS production rat and lower MMP levels. Mn-SOD, COX42, and mitochondrial biogenesis (PGC-1α, NRF1 and TFAM)-related proteins expression were consistent with animal levels. Conclusions Diabetes mellitus induces adverse atrial structural, electrophysiological remodeling, and mitochondrial damage and dysfunction. Metformin prevented these abnormalities through activation of the AMPK signaling pathway.

Protective Cardiovascular Effects of Metformin in Type 2 Diabetic Patients: Evidence and Underlying Mechanisms

Protective effects of metformin in various cardiovascular diseases: Clinical evidence and AMPK-dependent mechanisms

Cardiovascular protective effects of metformin

Cardioprotective Effects of Metformin

Therapeutic Potential of Metformin in Diabetes Mellitus-Related Cardiovascular Complications

Metformin and Cardiovascular Complications of Diabetes

Cardiovascular Protection by Metformin: Latest Advances in Basic and Clinical Research

Effects of Metformin on Diabetic Retinopathy and Its Mechanism

Biphasic Effect of Metformin on Human Cardiac Energetics

Mechanisms of action of metformin with special reference to cardiovascular protection

Novel Targets of Metformin in Cardioprotection: Beyond the Effects Mediated by AMPK

The Long-Term Cardiovascular Effects of Metformin on Patients with Newly Diagnosed Type 2 Diabetes

Lipid Profiling Reveals Different Therapeutic Effects of Metformin and Glipizide in Patients with Type 2 Diabetes and Coronary Artery Disease

The Cardioprotective Effects of Metformin in Myocardial Infarction Patients Without Diabetes: Current Status and Future Prospects

Metformin Improves Cardiac Function in Rats Via Activation of Amp-Activated Protein Kinase

AMPK is associated with the beneficial effects of antidiabetic agents on cardiovascular diseases

Metformin: An Old Drug for the Treatment of Diabetes but a New Drug for the Protection of the Endothelium

Metformin protects diabetes-induced atrial mitochondrial from oxidative stress and improves mitochondrial biogenesis via the AMPK signaling pathway

Metformin and Heart Failure

Metformin in therapeutic applications in human diseases: its mechanism of action and clinical study